Lymphovascular space invasion, a prognostic marker for disease recurrence in patients with early endometrioid endometrial cancer

• Authors: Seung Hyun Lee , Jung-Woo Park , Myeongsuk Han

Title variants

PL

Inwazja przestrzeni limfatycznej jako wskaźnik prognostyczny wznowy uchorych naendometrioidalnego raka trzonu macicy we wczesnym stopniu zaawansowania

• Languages of publication: EN

Abstracts

EN

Aim of the study: To evaluate the clinicopathologic factors of early International Federation of Gynecology and Obstetrics (FIGO) stage I–II endometrioid endometrial cancer in a single institution and to emphasize factors contributing to recurrence. Material and methods: We selected several clinicopathologic factors including age, height, body weight, body mass index, cancer antigen-125, FIGO tumor grade, myometrial invasion, lymphovascular space invasion, estrogen receptor/ progesterone receptor status, and adjuvant radiation therapy or systemic chemotherapy. Univariate and multivariate Cox proportional hazard model and Kaplan–Meier estimates were used for analyzing all clinicopathologic factors related to the risk of disease recurrence. Results: The median age was 55.05 years, and the median follow-up time was 35 months. Eleven patients (11%) showed disease recurrence, 3 patients – distant, and 8 patients – local metastasis. In univariate analysis, tumor grade (P = 0.0045) and lymphovascular space invasion (P = 0.0374) were associated with disease recurrence. Multivariate analysis demonstrated an association between any type of recurrence and lymphovascular space invasion (hazard ratio, HR, 6.308; 95% confidence interval, CI 1.851–11.484). Conclusions: Our study showed that the presence of lymphovascular space invasion is an important factor for disease recurrence in early endometrial cancer. Therefore, adjuvant systemic chemotherapy may be considered in patients with early endometrial cancer with lymphovascular space invasion.

PL

Celem pracy była ocena kliniczno-patologicznych cech endometrioidalnego raka błony śluzowej trzonu macicy w stadium I–II według klasyfikacji Międzynarodowej Federacji Ginekologii i Położnictwa (International Federation of Gynecology and Obstetrics, FIGO) w jednym ośrodku oraz podkreślenie czynników wpływających na wznowę choroby. Materiał i metody: W pracy wybrano kilka kliniczno-patologicznych czynników, takich jak wiek, wzrost, masa ciała, wskaźnik masy ciała, wartość antygenu nowotworowego CA-125, stopień w klasyfikacji FIGO, inwazja myometrium, inwazja przestrzeni limfatycznej, status receptorów estrogenowych/progesteronowych, a także radioterapia lub chemioterapia adiuwantowa. W celu oceny wszystkich cech kliniczno-patologicznych związanych z ryzykiem nawrotu choroby zastosowano jednoi wieloczynnikowy model proporcjonalnego ryzyka Coxa oraz analizę metodą Kaplana–Meiera. Wyniki: Mediana wieku wynosiła 55,05 roku, a mediana czasu obserwacji – 35 miesięcy. Nawrót choroby odnotowano u 11 chorych (11%): przerzuty odległe w 3, a wznowę miejscową w 8 przypadkach. W analizie jednoczynnikowej z nawrotem choroby powiązane były stopień złośliwości guza (P = 0,0045) oraz inwazja przestrzeni limfatycznej (P = 0,0374). Analiza wieloczynnikowa wykazała związek między każdym rodzajem nawrotu a inwazją przestrzeni limfatycznej (współczynnik ryzyka – hazard ratio, HR, 6,308; 95% przedział ufności CI 1,851–11,484). Wnioski: Wyniki niniejszego badania wskazują, że obecność inwazji przestrzeni limfatycznej jest ważnym czynnikiem nawrotu wczesnego raka endometrium. Można zatem rozważyć zastosowanie adiuwantowej chemioterapii u chorych na raka endometrium we wczesnym stopniu zaawansowania z inwazją przestrzeni limfatycznej.

Keywords

EN

endometrial cancer; lymphovascular space invasion; recurrence

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Communications
• Journal: Current Gynecologic Oncology
• Year: 2017
• Volume: 15
• Issue: 3
• Pages: 183–188

Contributors

author

Seung Hyun Lee

• Department of Obstetrics and Gynecology, Dong-A University, College of Medicine, 26, Daesingongwon-ro, Seo-gu, Busan, 49201, Republic of Korea

author

Jung-Woo Park

• Department of Obstetrics and Gynecology, Dong-A University, College of Medicine, 26, Daesingongwon-ro, Seo-gu, Busan, 49201, Republic of Korea

author

Myeongsuk Han

• Department of Obstetrics and Gynecology, Dong-A University, College of Medicine, 26, Daesingongwon-ro, Seo-gu, Busan, 49201, Republic of Korea

References

• 1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7–30.
• 2. Amant F, Moerman P, Neven P et al.: Endometrial cancer. Lancet 2005; 366: 491–505.
• 3. Kumar VJ, Nin CY, Kuei LY et al.: Survival and disease relapse in surgical stage I endometrioid adenocarcinoma of the uterus after adjuvant vaginal vault brachytherapy. Int J Gynecol Cancer 2010; 20: 564–569.
• 4. Zaino RJ, Kurman RJ, Diana KL et al.: Pathologic models to predict outcome for women with endometrial adenocarcinoma: the importance of the distinction between surgical stage and clinical stage – a Gynecologic Oncology Group study. Cancer 1996; 77: 1115–1121.
• 5. Creutzberg CL, van Putten WL, Koper PC et al.: Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000; 355: 1404–1411.
• 6. Nofech-Mozes S, Ackerman I, Ghorab Z et al.: Lymphovascular invasion is a significant predictor for distant recurrence in patients with early-stage endometrial endometrioid adenocarcinoma. Am J Clin Pathol 2008; 129: 912–917.
• 7. Long KC, Zhou Q, Hensley ML et al.: Patterns of recurrence in 1988 FIGO stage IC endometrioid endometrial cancer. Gynecol Oncol 2012; 125: 99–102.
• 8. Moschiano EJ, Barbuto DA, Walsh C et al.: Risk factors for recurrence and prognosis of low-grade endometrial adenocarcinoma; vaginal versus other sites. Int J Gynecol Pathol 2014; 33: 268–273.
• 9. Esselen KM, Boruta DM, del Carmen M et al.: Defining prognostic variables in recurrent endometrioid endometrial cancer: a 15-year single-institution review. Int J Gynecol Cancer 2011; 21: 1078–1083.
• 10. Hacker NF, Friedlander ML: Uterine cancer. In: Berek JS, Hacker NF (eds.): Berek & Hacker’s Gynecologic Oncology. 6th ed., Wolters Kluwer, Philadelphia 2015: 403–406.
• 11. Mariani A, Dowdy SC, Keeney GL et al.: High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy. Gynecol Oncol 2004; 95: 120–126.
• 12. Ayhan A, Tuncer ZS, Tuncer R et al.: Risk factors for recurrence in clinically early endometrial carcinoma: an analysis of 183 consecutive cases. Eur J Obstet Gynecol Reprod Biol 1994; 57: 167–170.
• 13. Cohn DE, Horowitz NS, Mutch DG et al.: Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer? Gynecol Oncol 2002; 87: 243–246.
• 14. Guntupalli SR, Zighelboim I, Kizer NT et al.: Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. Gynecol Oncol 2012; 124: 31–35.
• 15. Briët JM, Hollema H, Reesink N et al.: Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol Oncol 2005; 96: 799–804.
• 16. Keys HM, Roberts JA, Brunetto VL et al.: A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92: 744–751.
• 17. Morrow CP, Bundy BN, Kurman RJ et al.: Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991; 40: 55–65.
• 18. Gilani S, Anderson I, Fathallah L et al.: Factors predicting nodal metastasis in endometrial cancer. Arch Gynecol Obstet 2014; 290: 1187–1193.
• 19. Kondalsamy-Chennakesavan S, van Vugt S, Sanday K et al.: Evaluation of tumor-free distance and depth of myometrial invasion as prognostic factors for lymph node metastases in endometrial cancer. Int J Gynecol Cancer 2010; 20: 1217–1221.
• 20. Gemer O, Arie AB, Levy T et al.: Lymphvascular space involvement compromises the survival of patients with stage I endometrial cancer: results of a multicenter study. Eur J Surg Oncol 2007; 33: 644–647.
• 21. Giatromanolaki A, Koukourakis MI, Turley H et al.; Tumour and Angiogenesis Research Group: Phosphorylated KDR expression in endometrial cancer cells relates to HIF1α/VEGF pathway and unfavourable prognosis. Mod Pathol 2006; 19: 701–707.
• 22. Alektiar KM, McKee A, Lin O et al.: The significance of the amount of myometrial invasion in patients with Stage IB endometrial carcinoma. Cancer 2002; 95: 316–321.
• 23. ASTEC/EN.5 Study Group; Blake P, Swart AM, Orton J et al.: Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 2009; 373: 137–146.

• Document Type: article